Cargando…

Current Immunotherapies for Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor found in the central nervous system. Currently, standard treatments in the clinic include maximal safe surgical resection, radiation, and chemotherapy and are mostly limited by low therapeutic efficiency correlated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Boyuan, Li, Xuesong, Li, Yuntao, Zhang, Jin, Zong, Zhitao, Zhang, Hongbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986847/ https://www.ncbi.nlm.nih.gov/pubmed/33767690 http://dx.doi.org/10.3389/fimmu.2020.603911

Ejemplares similares

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies
por: Huang, Boyuan, et al.
Publicado: (2023)

Advances in immunotherapy for glioblastoma multiforme
por: Mahmoud, Ahmad Bakur, et al.
Publicado: (2022)

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
por: Pearson, Joshua R. D., et al.
Publicado: (2020)

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas
por: Zhang, Hongbo, et al.
Publicado: (2020)

Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects
por: Chowdhury, Selia, et al.
Publicado: (2021)

Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
por: Park, Jang Hyun, et al.
Publicado: (2022)

Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme
por: Chen, Anjing, et al.
Publicado: (2022)

Immunotherapy for Glioblastoma: Current Progress and Challenges
por: Yu, Miranda W., et al.
Publicado: (2021)

Cell-based immunotherapy of glioblastoma multiforme
por: Bryukhovetskiy, Igor
Publicado: (2022)

Erratum: Immunotherapy for Glioblastoma: Current Progress and Challenges
Publicado: (2021)

PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
por: Zhu, Zhiyuan, et al.
Publicado: (2020)

Human Endogenous Retroviruses in Glioblastoma Multiforme
por: Yuan, Zihao, et al.
Publicado: (2021)

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions
por: Wang, Mingming, et al.
Publicado: (2023)

Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme
por: Xu, Xun, et al.
Publicado: (2012)

Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
por: Jackson, Christopher, et al.
Publicado: (2011)

Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme
por: Chin, Christopher, et al.
Publicado: (2018)

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
por: Jan, Chia-Ing, et al.
Publicado: (2018)

Current data and strategy in glioblastoma multiforme
por: Iacob, G, et al.
Publicado: (2009)

Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme
por: Schuessler, Andrea, et al.
Publicado: (2014)

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
por: Yang, Liu, et al.
Publicado: (2015)

Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme
por: Cai, Xiaomin, et al.
Publicado: (2022)

Putting Proteomics Into Immunotherapy for Glioblastoma
por: Chen, Liangyu, et al.
Publicado: (2021)

The immunosuppressive microenvironment and immunotherapy in human glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2022)

Current Trends in Targeted Therapies for Glioblastoma Multiforme
por: Ohka, Fumiharu, et al.
Publicado: (2012)

Current and Future Novel Treatments for Glioblastoma Multiforme
por: Tyler, Betty, et al.
Publicado: (2014)

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma
por: Tang, Lin, et al.
Publicado: (2022)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme
por: Zhang, Yan, et al.
Publicado: (2018)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Corrigendum: Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme
por: Zhang, Yan, et al.
Publicado: (2020)

Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme
por: Mu, Long, et al.
Publicado: (2022)

Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy
por: Feng, Peng, et al.
Publicado: (2022)

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
por: Yalamarty, Satya Siva Kishan, et al.
Publicado: (2023)

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
por: Kuan, Chien-Tsun, et al.
Publicado: (2010)

SYST-31 PROBIOTIC DELIVERY TO ORTHOTOPIC GLIOBLASTOMA MULTIFORME MODELS AS AN IMMUNOTHERAPY
por: Windemuth, Sophia, et al.
Publicado: (2023)

Exploring the multidimensional heterogeneities of glioblastoma multiforme based on sample-specific edge perturbation in gene interaction network
por: Zheng, Jianglin, et al.
Publicado: (2022)

Nanotechnology for Treatment of Glioblastoma Multiforme
por: Michael, Justin S., et al.
Publicado: (2018)

Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme
por: Lee, Mijeong, et al.
Publicado: (2019)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a98o7vhkj1i1lf1rl3kpv6rebl